Trials / Completed
CompletedNCT00127010
Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases
Blinded, Randomized Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Measles-mumps-rubella-varicella Candidate Vaccine Given to Healthy Children During the Second Year of Life
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 11 Months – 13 Months
- Healthy volunteers
- Accepted
Summary
This is a study to evaluate the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals combined measles-mumps-rubella varicella candidate vaccine given to healthy children in their second year of life.
Detailed description
This study included an active control group who received the licensed Priorix (measles, mumps, rubella \[MMR\] vaccine).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Measles, Mumps, Rubella and Chickenpox (live vaccine) |
Timeline
- Start date
- 2005-11-01
- Completion
- 2006-06-01
- First posted
- 2005-08-05
- Last updated
- 2016-09-26
Locations
48 sites across 3 countries: Belgium, Germany, Netherlands
Source: ClinicalTrials.gov record NCT00127010. Inclusion in this directory is not an endorsement.